Celebrating 25 years Est 1999-2024
*Across 3 years $2276.64 only $1138.32
FORM 3 UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. ...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
TapImmune And Marker Therapeutics Announce Successful Closing Of Previously Announced Merger And Financing...
FORM 4 [ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
TapImmune's HER2/neu-Targeted Breast Cancer Vaccine to be Studied in a Large Phase 2 Immunotherapy Combination...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.